# Dupilumab and House Dust Mite Immunotherapy in Patients With Atopic Dermatitis

> **NCT06509243** · NA · COMPLETED · sponsor: **Medical University of Silesia** · enrollment: 132 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **BIOLOGICAL:** tablets Acarizax
- **BIOLOGICAL:** dupilumab
- **DRUG:** cyclosporine

## Key facts

- **NCT ID:** NCT06509243
- **Lead sponsor:** Medical University of Silesia
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-10
- **Primary completion:** 2024-03-12
- **Final completion:** 2024-04-10
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2024-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06509243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06509243, "Dupilumab and House Dust Mite Immunotherapy in Patients With Atopic Dermatitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06509243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*